Sales of PCSK9 inhibitors fall short of expectations

Sales of two cholesterol-lowering medications that the FDA approved last summer have fallen far short of expectations, the Associated Press reports. 

The FDA approval of the first two proprotein convertase subtilisin/kexin type 9 inhibitors (evolocumab and alirocumab) received national attention in 2015. However, the Associated Press notes that Sanofi reported meager alirocumab sales of just $10 million last quarter, while Amgen did not report evolocumab sales.

Read more at the link below: